Inclusion Criteria:

- 18-75 years old,male and female

- Mainly based on the criteria for liver cancer TNM stage I and II (edition 7) and BCLC
stage A, the following needs to be satisfied:

1. individual tumor larger than or equal to 2 cm and smaller than or equal to 10 cm
in the maximum diameter

2. multiple tumors with no more than three tumors

3. No macroscopic tumor embolus

- ECOG performance state is 0-1

- Child-Pugh grade is A

- The clinical review confirms the absence of recurrence within 8 weeks before the
enrollment

- Sign the informed consent

Exclusion Criteria:

- Pregnant and breast-feeding women

- Patients with severe diseases in the brain, heart,lungs, kidneys and
hematological system

- Patients who have received other anti-tumor therapies before the surgery (including
liver transplantation, TACE, local tumor ablation, chemotherapy, radiotherapy,
molecular targeted therapy and other anti-tumor therapy)

- DDS chemotherapy pump placed in the portal vein during the surgery

- Patients who are participating in other drug trials

- Patients known or suspected to be allergic to ginsenoside, with a history of allergy
to biological preparations, allergic constitution or currently in an allergic state;

- With active severe clinical infection

- Epilepsy episode which needs drug therapy

- With a history of allotransplantation;

- With a previous history of tumor in other systems, but except for:

1. Carcinoma in situ of cervix

2. Basal cell carcinoma after treatment,Superficial bladder cancer (Ta, Tis and T1

3. Any cancer after curative treatment no less than three years ago

- Patients with signs or a history of bleeding diathesis

- Patients currently receiving kidney dialysis

- A history of bleeding in the gastrointestinal tract within 30 days, or severe
gastroesophageal varices with red signs; with a history of gastroesophageal variceal
hemorrhage

- Recurrent HCC

- Patients unable to take drug orally

- Patients inappropriate to participate in the trial upon the investigator's judgment